Navigation Links
New pyrimidine compounds may lead to improved treatments for childhood brain cancer
Date:4/6/2010

April 6, 2010 (Philadelphia, PA) -- Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. Src represents one of the most promising targets for cancer therapy.

A recent study shows that pyrazolo-[3,4-d]pyrimidine-derivatives, designed to target Src, may be effective in interfering with the cell cycle and causing cancer cell death in medulloblastoma. The results were published in FASEB (The Journal of the Federation of American Societies for Experimental Biology) and were funded by the Sbarro Health Research Organization Center for Biotechnology (www.shro.org), a nonprofit group devoted to molecular and genetic research located at the College of Science and Technology at Temple University in Philadelphia, PA and the Human Health Foundation (www.hhfonlus.org), a nonprofit biotechnology research organization located in Terni, Italy.

"Our aim was to investigate the inhibitory effects of new pyrimidine-derivatives," said lead author Antonio Giordano, M.D. PhD, the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine and a 'Chiara fama' Professor at the Department of Human Pathology and Oncology, University of Siena, Siena, Italy. "Our findings show that, in medulloblastoma cells, pyrimidine derivatives can downregulate Src activity and reduce cell proliferation and tumor progression in vivo. This suggests that pyrimidine derivatives could be an effective therapeutic strategy not only for the treatment of medulloblastomas, but also for other Src expressing tumors."

Although better treatment regimens, including surgery, chemotherapy and radiotherapy have substantially improved survival, medulloblastoma remains incurable in about one third of patients and current treatments can cause toxic neurocognitive side effects.

"Compared with conventional chemotherapeutic agents cisplatin and etoposide that are presently used in medulloblastoma therapy, we found that these pyrimidine derivatives show major inhibitory effects on cell proliferation," said Alessandra Rossi, Ph.D, a co-author of the study, a Research Fellow at the Sbarro Institute. "Using these compounds with radiotherapy could allow the reduction of radiation doses and, consequently, the avoidance of radiotherapy-related cognitive and endocrine toxic effects. Moreover, our findings reveal that the pyrimidine compounds showed synergistic effects when combined with cisplatin and etoposide, suggesting their possible use in association with chemotherapy."

Attempts to further reduce the morbidity and mortality associated with medulloblastoma have been limited by the toxicity of conventional treatments and the low permeability of the blood-brain barrier (BBB), which restricts the entry of hydrophilic and large liphophilic compounds into the brain.

"Other Src inhibitors, currently in clinical trials for the treatment of other pathologies, showed low efficacy in the treatment of metastasis to the brain," said co-author Silvia Schenone, Ph.D, Associate Professor at the University of Genoa, Genoa, Italy, in collaboration with Maurizio Botta, Ph.D, Adjunct Professor at Temple University, Director, Drug Discovery Program, Professor Medical Chemistry and Dean of the Faculty of Pharmacy at the University of Siena, Siena, Italy. "But our pyrimidine derivatives have liphophilic characteristics, which enable them to pass through the blood brain barrier more easily, representing an other advantage of their use in medulloblastoma therapy."

Besides the possible use of these pyrimidine derivatives in the treatment of medulloblastoma, these compounds could be useful to develop new pharmacologic inhibitors to study the physiological and oncogenic functions of Src.


'/>"/>

Contact: Ilene Rush
irush@shro.org
215-470-2998
Sbarro Health Research Organization
Source:Eurekalert

Related medicine news :

1. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
2. Compounds Identified That Might Treat Nerve Diseases
3. Prenatal exposure to flame-retardant compounds affects neurodevelopment of young children
4. Marijuana Compounds Could Beat Back Brain Cancer
5. Spice Compounds May Stem Tumor Growth
6. Foster care associated with improved growth, intelligence compared to orphanage care
7. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
8. Improved patient care with telemonitoring
9. Improved doctor-pharmacist collaboration needed: study
10. An improved method for calculating tumor growth
11. TeraMedica Unveils Improved Univision, Now Offering a Multi-Layer Enterprise Viewing Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a comprehensive ... Dr. Brian Seese leads the practice as a skilled and highly credentialed dentist who ... by Seese serves patients of all ages with excellence in general, restorative, and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, ... should be asking before selecting an FDA approval pathway? , How should ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... 2017 season , Trinity Health and the U.S. Soccer Foundation announced today that ... in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
(Date:2/16/2017)... (PRWEB) , ... February 17, 2017 , ... ... their experience can last long after their final treatments. Physician researchers at ... neuro-emotional technique (NET), a mind-body therapy, for efficacy in reducing symptoms of traumatic ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 2017  Express Scripts (NASDAQ: ESRX ) was recognized ... Companies within the Health Care: Pharmacy and Other Services category. ... World,s Most Admired Companies," said Tim Wentworth , CEO and ... passion of our 26,000 employees to make medicine more affordable and ... ...
(Date:2/16/2017)...  Prescription pain medications provided by "physicians in the ... long-term opioid use to take hold," according to a ... of The New England Journal of Medicine ... in acute pain than in almost any other medical ... of the American College of Emergency Physicians. "The challenge ...
(Date:2/16/2017)... , Feb. 16, 2017   Spectralink ... solutions for the healthcare, retail, manufacturing and hospitality ... on the performance and symbology support features of ... a dual-mode camera/barcode scanner. The study, conducted by ... the PIVOT:SC to two phones with dedicated hardware ...
Breaking Medicine Technology: